*Non-Active Secondary Progressive Multiple Sclerosis (expanded program; n=10) ** Grant from Amyotrophic Lateral Sclerosis Association for development
Technology - Foralumab
A Novel Intranasal Immunotherapy to Reduce Neuroinflammation
Intranasal foralumab is successfully delivered to the cervical lymph nodes through a convenient nasal administration.
It binds to the surface of a CD4+ or a CD8+ T Cell.
This stimulates the development of anti-inflammatory producing IL-10 T Regs.
These T Regs migrate into the CNS where they infiltrate the blood brain barrier and produce IL-10 to promote a switch in the activated microglial state to an anti-inflammatory homeostatic state.
Additionally, these IL-10 suppress other cells of the CNS including astrocytes which reduces blood brain barrier degradation
These mechanisms help defend the CNS against chronic inflammatory damage.
Because of this, nasally administered foralumab is a promising therapeutic for numerous neuroinflammatory and neurodegenerative diseases.
Find Reports Sources And More: TLSA Website. TLSA Presentation. -----
5 Key Reasons Why (Nasdaq: TLSA) Holds Our Top Watchlist Spot Thursday
#1. A Newly Upgraded $9 Analyst Target: This week, TLSA earned an upgraded target of $9.00 from Lucid Capital Markets.
From its closing valuation on Wednesday, this target suggests TLSA may have a potential 450+% upside.
#2. Chart Support May Be Strengthening At Key Technical Levels.
TLSA ended Wednesday's session in a noteworthy spot on its chart.
The Nasdaq profile closed above five important technical levels, suggesting that chart support may be gaining momentum.
These 5 technical levels could be building strength:
- 5-Day Simple Moving Average (SMA)
- 20-Day SMA
- 50-Day SMA
- 5-Day Exponential Moving Average (EMA)
- 13-Day EMA
Keep an eye on TLSA’s chart, as its 200-Day SMA was tested and momentarily broken through on Wednesday.
#3. Tiziana Announced New Positive Clinical Data for Intranasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis.
Tiziana Life Sciences reported encouraging updated clinical data from its Expanded Access ("EA") Program evaluating intranasal foralumab in 14 patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
Over extended treatment, the therapy remained highly well tolerated with no new safety concerns.
Patients exhibited stabilization of disability and meaningful improvements in fatigue, key outcomes in a condition with limited options.
These results strengthen confidence in foralumab’s potential as a differentiated, non-invasive treatment and support continued advancement toward regulatory approval and broader clinical adoption.
#4. Tiziana Reported Reduced Brain Inflammation in Multiple System Atrophy Patients Treated with Intranasal Foralumab.
Tiziana Life Sciences announced compelling early Phase 2 data showing intranasal foralumab significantly reduced brain inflammation in two patients with Multiple System Atrophy ("MSA").
PET scans revealed up to 35% reductions in standardized uptake value (SUV) and approximately 24% reduction in standardized uptake value ratio (SUVR) in affected areas of the brain.
Foralumab continues to demonstrate consistent anti-inflammatory benefits across multiple neurological indications.
These findings build on prior success in multiple sclerosis and Alzheimer’s disease, reinforcing the therapy’s broad applicability and positioning Tiziana at the forefront of innovative treatments for neurodegenerative diseases with high unmet need.
#5. Tiziana Life Sciences Announced Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long CVD Neuroinflammation and Improves Cognitive Function.
Tiziana Life Sciences announced the publication of positive preclinical data in a bioRxiv preprint.
The study demonstrated that nasal anti-CD3 treatment significantly reduces neuroinflammation, boosts regulatory T cells (Tregs) in the brain, restores hippocampal neurogenesis, and improves short-term memory in a model of Long CVD.
Independent academic collaboration strengthens credibility and translational relevance, supported by human data linking reduced Tregs to symptoms.
As a non-invasive immunomodulatory approach, foralumab shows potential to address widespread “brain fog.”
These results expand Tiziana’s pipeline opp's and validate its platform across multiple neuroinflammatory conditions, supporting future clinical development initiatives. -----
Coverage is officially underway on Tiziana Life Sciences, Ltd. (Nasdaq: TLSA).
Updates will be heading your way soon. Be on the lookout.
All the best, Dane James Editor Market Pulse Today
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 05/21/2026 and ending on 05/21/2026 to publicly disseminate information about (TLSA:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the sixty thousand USD funds that TD Media LLC received from a third party named Sica Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (TLSA:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/tlsa-vconj/#details |
